🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 01/04/2008 | 23,40 | 25,60 | 23,40 | 25,41 | +6,36% | 9,40% | 9.992.100 |
| 31/03/2008 | 20,34 | 24,20 | 19,99 | 23,89 | +28,03% | 20,70% | 17.809.700 |
| 28/03/2008 | 19,27 | 19,47 | 18,55 | 18,66 | -2,96% | 4,77% | 2.600.800 |
| 27/03/2008 | 18,24 | 20,17 | 18,10 | 19,23 | +7,85% | 11,35% | 5.029.500 |
| 26/03/2008 | 18,08 | 18,42 | 17,67 | 17,83 | -2,03% | 4,15% | 1.545.900 |
| 25/03/2008 | 18,00 | 18,66 | 17,90 | 18,20 | +1,73% | 4,22% | 3.018.800 |
| 24/03/2008 | 16,47 | 18,11 | 16,47 | 17,89 | +8,69% | 9,96% | 3.678.500 |
| 20/03/2008 | 15,55 | 16,54 | 15,45 | 16,46 | +5,85% | 7,01% | 4.214.700 |
| 19/03/2008 | 14,97 | 15,86 | 14,97 | 15,55 | +3,53% | 5,95% | 3.306.600 |
| 18/03/2008 | 14,90 | 15,04 | 14,22 | 15,02 | +2,04% | 5,50% | 3.066.500 |
| 17/03/2008 | 15,07 | 15,36 | 14,54 | 14,72 | -4,66% | 5,44% | 2.366.100 |
| 14/03/2008 | 15,43 | 15,53 | 14,89 | 15,44 | +0,92% | 4,15% | 3.304.100 |
| 13/03/2008 | 15,49 | 15,62 | 14,99 | 15,30 | -1,29% | 4,07% | 4.081.100 |
| 12/03/2008 | 14,99 | 16,00 | 14,95 | 15,50 | +4,59% | 7,00% | 4.424.300 |
| 11/03/2008 | 15,10 | 15,16 | 13,84 | 14,82 | +1,58% | 8,74% | 5.009.600 |
| 10/03/2008 | 16,03 | 16,03 | 14,52 | 14,59 | -9,15% | 9,42% | 3.226.100 |
| 07/03/2008 | 15,86 | 16,20 | 15,47 | 16,06 | +0,88% | 4,60% | 3.356.800 |
| 06/03/2008 | 16,86 | 17,18 | 15,91 | 15,92 | -6,08% | 7,53% | 2.660.600 |
| 05/03/2008 | 17,42 | 17,69 | 16,81 | 16,95 | -2,64% | 5,05% | 2.056.700 |
| 04/03/2008 | 17,53 | 17,53 | 16,94 | 17,41 | -0,97% | 3,37% | 1.894.700 |
| 03/03/2008 | 17,48 | 17,89 | 17,36 | 17,58 | +0,46% | 3,03% | 1.673.100 |
| 29/02/2008 | 18,25 | 18,35 | 17,18 | 17,50 | -4,99% | 6,41% | 3.364.000 |
| 28/02/2008 | 18,52 | 18,77 | 18,20 | 18,42 | -1,07% | 3,08% | 1.636.800 |
| 27/02/2008 | 19,16 | 19,23 | 18,38 | 18,62 | -2,72% | 4,44% | 1.732.500 |
| 26/02/2008 | 18,50 | 19,52 | 18,22 | 19,14 | +3,57% | 7,03% | 3.013.200 |
| 25/02/2008 | 18,27 | 19,57 | 18,19 | 18,48 | +2,16% | 7,55% | 6.400.800 |
| 22/02/2008 | 17,65 | 18,14 | 17,57 | 18,09 | +2,03% | 3,23% | 3.811.000 |
| 21/02/2008 | 18,00 | 18,11 | 17,62 | 17,73 | -1,83% | 2,72% | 3.531.500 |
| 20/02/2008 | 17,69 | 18,08 | 17,37 | 18,06 | +1,46% | 4,01% | 3.356.800 |
| 19/02/2008 | 18,60 | 18,60 | 17,79 | 17,80 | -3,21% | 4,35% | 3.475.800 |